anti-CD16/CD33 bispecific killer cell engager antibody (University of Minnesota)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD16/CD33 bispecific killer cell engager antibody (University of Minnesota)

Drug Alias Nameanti-CD16/anti-CD33 bispecific NK-cell engager (University of Minnesota)anti-CD16/anti-CD33 bispecific immune-cell engager (University of Minnesota)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsLow affinity immunoglobulin gamma Fc region receptor III agonists

TargetsLow affinity immunoglobulin gamma Fc region receptor IIIMyeloid cell surface antigen CD33

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Minnesota

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Of Minnesota

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A